Back to Search
RANJANA ADVANI, MD
MD
Medical Oncology Physician
NPI: 1639225121IndividualAccepts Medicare
Specialties, Licenses & Credentials
Medical Oncology PhysicianPrimary
Internal Medicine — Medical Oncology
Code: 207RX0202X
A44422(CA)
Education
OTHER
Class of 1982
Research & Publications (20)
Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma.
PMID 19636010·J Clin Oncol·2009
3-trial
Impact of positive positron emission tomography on prediction of freedom from progression after Stanford V chemotherapy in Hodgkin's disease.
PMID 17664458·J Clin Oncol·2007
8-other
Angioimmunoblastic T cell lymphoma: treatment experience with cyclosporine.
PMID 17454592·Leuk Lymphoma·2007
4-observational
A phase I trial of aprinocarsen (ISIS 3521/LY900003), an antisense inhibitor of protein kinase C-alpha administered as a 24-hour weekly infusion schedule in patients with advanced cancer.
PMID 16133798·Invest New Drugs·2005
3-trial
A phase I trial of liposomal doxorubicin, paclitaxel and valspodar (PSC-833), an inhibitor of multidrug resistance.
PMID 16126736·Ann Oncol·2005
3-trial
Stage I and II follicular non-Hodgkin's lymphoma: long-term follow-up of no initial therapy.
PMID 15024027·J Clin Oncol·2004
8-other
A Phase II trial of aprinocarsen, an antisense oligonucleotide inhibitor of protein kinase C alpha, administered as a 21-day infusion to patients with advanced ovarian carcinoma.
PMID 14716767·Cancer·2004
3-trial
Phase I and pharmacokinetic study of BMS-188797, a new taxane analog, administered on a weekly schedule in patients with advanced malignancies.
PMID 14613998·Clin Cancer Res·2003
3-trial
Plasmablastic lymphoma presenting in a human immunodeficiency virus-negative patient: a case report.
PMID 12783213·Ann Hematol·2003
5-case
A phase I trial of doxorubicin, paclitaxel, and valspodar (PSC 833), a modulator of multidrug resistance.
PMID 11350887·Clin Cancer Res·2001
3-trial
The emerging role for rituximab in the treatment of nodular lymphocyte predominant Hodgkin lymphoma.
PMID 19606035·Curr Opin Oncol·2009
6-review
Prognostic factors in primary cutaneous anaplastic large cell lymphoma: characterization of clinical subset with worse outcome.
PMID 19528422·Arch Dermatol·2009
8-other
Identification and testing of control peptides for antigen microarrays.
PMID 19162032·J Immunol Methods·2009
8-other
Indolent primary cutaneous B-cell lymphoma: experience using systemic rituximab.
PMID 18817999·J Am Acad Dermatol·2008
8-other
Evaluation and management of angioimmunoblastic T-cell lymphoma: a review of current approaches and future strategies.
PMID 19209140·Clin Adv Hematol Oncol·2008
6-review
Paraffin-based 6-gene model predicts outcome in diffuse large B-cell lymphoma patients treated with R-CHOP.
PMID 18445689·Blood·2008
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 300 PASTEUR DR
STANFORD, CA 94305 - Phone
- (650) 723-4000
Quick Facts
- NPI
- 1639225121
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 44
- Publications
- 20
Are you this provider?
Claim Your Profile